<DOC>
	<DOCNO>NCT00076635</DOCNO>
	<brief_summary>Open-label therapy administer 220 patient , follow completion either InterMune Protocol GIPF-002 Part B Protocol GIPF-004 , assess long-term safety subcutaneous Interferon gamma-1b . The study duration 5 year .</brief_summary>
	<brief_title>An Open-Label Study Safety Interferon Gamma-1b Patients With IPF</brief_title>
	<detailed_description>Open-label therapy administer subcutaneously . Patients enrol continue receive Interferon gamma-1b therapy three time per week evaluate 6-week interval . Patients take Interferon gamma-1b enrollment re-initiate therapy subcutaneous Interferon gamma-1b dose-escalation scheme , reach full dose 2 week .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion criterion : Enrollment Protocol GIPF 002 Part B GIPF004 Completion End Treatment Visit Protocol GIPF002 Part B Study Completion Visit GIPF004 Able understand sign write informed consent form comply requirement study Exclusion criterion : pregnancy lactation lack adherence either GIPF002 GIPF004 study protocol treatment regimens Principal Investigator deem patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Lung</keyword>
	<keyword>Actimmune</keyword>
	<keyword>Interferon</keyword>
	<keyword>Gamma</keyword>
	<keyword>InterMune</keyword>
</DOC>